The production and characterization of two new monoclonal antibodies (MAbs), designated MAR4 and MAR5, raised against the partially purified α5β1 integrin, are described. The reactivity of these 2 MAbs on tumor cell lines indicated that they reacted on all the cells expressing the β1 subunit independently of the α5 expression. Both MAbs were found to immunoprecipitate on 3 cell lines, a protein of 120 KD corresponding to the molecular weight be the β1 chain, in addition to proteins of other MW corresponding to the α subunits differentially expressed by these cells. The cross-competition experiments showed that MAR4 and MAR5 recognize the same epitope. These 2 MAbs seem to be useful reagents for the characterization of the VLA expression in tumor cells.
Get full access to this article
View all access options for this article.
References
1.
AkiyamaS.K., YamadaS.S., ChenW.T., YamadaK.M.: Analysis of fibronectin receptor function with monoclonal antibodies: Roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization.J. Cell Biol., 109: 863–875, 1989.
2.
BossyB., Bossy-WetzelE., ReichardtL.F.: Characterization of the integrin α8 subunit: A new integrin Pi-associated sub-unit, which is prominently expressed on axons and on cells in contact with basal laminae in chick embryos.EMBO J., 10: 2375–2385, 1991.
3.
CanevariS., OrlandiR., RipamontiM., TagliabueE., AguannoA., MiottiS., MenardS., ColnaghiM.I.: Ricin A chain conjugated to monoclonal antibodies selectively kills human carcinoma cells in vitro.J. Natl. Cancer Inst., 75: 831, 1985.
4.
CassimanJ.-J.: The involvement of the cell matrix receptors, or VLA integrins, in the morphogenetic behaviour of normal and malignant cells is gradually being uncovered.Cancer Genet. Cytogenet., 41: 19–32, 1989.
5.
ConfortiG., ZanettiA., ColellaS., AbbadiniM., MarchisioP.C., PytelaR., GiancottiF.G., TaroneG., LanguinoL.R., DejanaE.: Interaction of fibronectin with cultured human endothelial cells: Characterization of the specific receptor.Blood, 73: 1576–1585, 1989.
6.
DedharS.: Integrins and tumor invasion.BioEssays, 12: 583–590, 1990.
7.
EyP.L., ProwseS.L., JenkinC.R.: Isolation of pure IgG., IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose, Immunochemistry, 15: 429–436, 1978.
8.
GehlsenK.R., ArgravesW.S., PierschbacherD., RouslahtiE.: Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides.J. Cell Biol., 106: 925–930, 1988.
9.
GiancottiF.G., RuoslahtiE.: Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells.Cell, 60: 849–859, 1990.
10.
HemlerM.E.: VLA proteins in the integrin family: structures, functions, and their role on leukocytes.Annu. Rev. Immunol., 8: 365–400, 1990.
11.
KaufmanR., FroschD., WestphalC., WeberL., KleinC.E.: Integrin VLA-3: Ultrastructural localization at cell-cell contact sites of human cell cultures.J. Cell Biol., 109: 1807–1815, 1989.
12.
KramerR.H., McDonaldK.A., VuM.P.: Human melanoma cells express a novel integrin receptor for laminin.J. Biol. Chem., 264(26): 15642–15649, 1989.
13.
LaemmliU.K.: Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature, 227: 6801970.
14.
MenardS., TagliabueE., CanevariS., FossatiG., ColnaghiM.I.: Generation of monoclonal antibodies reacting with normal cancer cells of human breast.Cancer Res., 43: 1295–1300, 1983.
15.
MiottiS., CanevariS., MenardS., MezzanzanicaD., PorroG., PupaS.M., RegazzoniM., TagliabueE., ColnaghiM.I.: Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.Int. J. Cancer, 39: 297–303, 1987.
16.
MortariniR., AnichiniA., ParmianiG.: Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins.Int. J. Cancer, 47: 551–559, 1991.
17.
PignatelliM., BodmerW.F.: Genetics and biochemistry of collagen binding-triggered glandular differentiation in a human colon carcinoma cell line.Proc. Natl. Acad. Sci. USA, 85: 5561–5565, 1988.
18.
PlantefaberL.C., HynesR.O.: Changes in integrin receptors on oncogenically transformed cells.Cell, 56: 281–290, 1989.
19.
RuoslahtiE.: Integrins. J. Clin. Invest., 87: 1–5, 1991.
